Diagnosis, Management, and Prevention of Hepatitis B Reactivation

Lee, Hannah M.; Liapakis, AnnMarie; Lim, Joseph K.

doi:10.1007/s11901-015-0271-9

Cited by 3 publications

(6 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The general classification of HBV reactivation is based on HBV biomarkers, type of immunosuppressive therapy and/ or use of glucocorticoid combined therapy (64)(65)(66)(67)(68)(69)(70). Among patients with a positive HBsAg or anti-HBc biomarkers, a very high risk of HBV reactivation (>20%) is associated with anti-CD20 monoclonal antibody agents (rituximab, obinutuzumab, ofatumumab) (37,50,(64)(65)(66)(67)(68)(71)(72)(73).…”

Section: Risk Stratification Of Hbv Reactivationmentioning

confidence: 99%

Optimizing antiviral agents for hepatitis B management in malignant lymphomas

et al. 2017

View full text Add to dashboard Cite

Abstract:The global scale of hepatitis B infection is well known but its impact is still being understood. Missed hepatitis B infection impacts lymphoma therapy especially increased risk of hepatitis B virus (HBV) reactivation and poor treatment outcomes. The presence of undiagnosed chronic hepatitis also undermines chronic HBV screening methods that are based on a positive HBsAg alone. The goal of this review is to evaluate the literature for optimizing antiviral therapy for lymphoma patients with HBV infection or at risk of HBV reactivation.Relevant articles for this review were identified by searching PubMed, Embase, Ovid Medline, and Scopus using the following terms, alone and in combination: "chronic hepatitis B", "occult hepatitis B", "special groups", "malignant lymphoma", "non-Hodgkin's lymphoma", "Hodgkin's lymphoma", "immunocompromised host", "immunosuppressive agents", "antiviral", "HBV reactivation". The period of the search was restricted to a 15-year period to limit the search to optimizing antiviral agents for HBV infection in malignant lymphomas [2001][2002][2003][2004][2005][2006][2007][2008][2009][2010][2011][2012][2013][2014][2015][2016].Several clinical practice guidelines recommend nucleos(t)ide analogues-entecavir, tenofovir and lamivudine among others. These agents are best initiated along with or prior to immunosuppressive therapy. Additional methods recommended for optimizing antiviral therapy include laboratory modalities such as HBV genotyping, timed measurements of HBsAg and HBV DNA levels to measure and predict antiviral treatment response. In conclusion, optimizing antiviral agents for these patients require consideration of geographic prevalence of HBV, cost of antiviral therapy or testing, screening modality, hepatitis experts, type of immunosuppressive therapy and planned duration of therapy. Prevalence of chronic hepatitis B (CHB) by region, age group and special groups (lymphoma)The hepatitis B virus (HBV) is a common human infection which belongs to the hepadnaviridae family. The chronic form of HBV infection is more prevalent than the acute type, and global estimate of chronic cases is 300 million or more (1-3). Despite the likelihood that 95% of adults will recover from an acute HBV infection, impaired viral clearance facilitates complications such as chronic hepatic inflammation, hepatocellular carcinoma and lymphomas (4-7). On a global scale, the mortality from HBV complications is estimated at about 780,000-1 million yearly and adds to existing burdens to health systems (2,8). Global estimates of CHB prevalence indicate high prevalence of CHB in the African and Western pacific region and countries with the highest number of HBsAg-positive individuals include China (74 million), India (17 million) and Nigeria (15 million) (9). Significant decrease in CHB prevalence has been recorded over the last 5 decades especially in countries Review Article on Treatment for Hepatitis B

show abstract

Section: Risk Stratification Of Hbv Reactivationmentioning

confidence: 99%

Optimizing antiviral agents for hepatitis B management in malignant lymphomas

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Patients who received anti-CD20 monoclonal antibodies, such as rituximab, were at the highest risk for HBV reactivation. 29 , 30 …”

Section: Hepatitis B Reactivation In Nhl Therapymentioning

confidence: 99%

“… 14 , 35 In addition, reactivation rates may be reduced due to early diagnosis and increased knowledge of the management of chronic hepatitis B and the associated HBV reactivation in oncologic therapy. 30 , 36…”

Section: Hepatitis B Reactivation In Nhl Therapymentioning

confidence: 99%

“…Screening for both HBV reactivation and HBV risk factors is the first step in preventing reactivation in patients undergoing therapy for NHL. 28 , 30 , 53 Organizational policies on screening have significantly increased screening rates over the last 6 years from 20% to 90% at large oncology centers in the US. 24 , 28 Policies on screening modalities are also gradually shifting from a targeted approach to a universal approach.…”

Section: Prevention Strategiesmentioning

confidence: 99%

“…The literature suggests that prophylaxis against rituximab associated HBV-reactivation should be extended up to 12 months following oncologic therapy and should be combined with HBV viral load surveillance every 3 months. 30 , 53 , 57 Although NCCN warns against lamivudine as a routine prophylactic agent due to risk of viral resistance, AASLD, EASL, ASIF, and APASL recommend lamivudine as a viable prophylactic agent based on its pharmaco-economic and safety profiles. 59 – 61 , 88 Specifically, the AASLD endorses lamivudine when the planned duration of chemotherapy is less than 12 months and entecavir or tenofovir for chemotherapy lasting beyond 12 months.…”

Section: Prevention Strategiesmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin’s Lymphoma and Prevention Strategies

Ozoya

Sokol

Dalia³

2016

JCTH

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic vaccines. Non-Hodgkin’s lymphoma is the most common hematological malignancy, and certain patients undergoing therapy are at increased risk of HBV reactivation. Rituximab, a monoclonal antibody, is well studied in HBV reactivation, but newer agents have been implicated as well. Here, we review novel agents suspected in HBV reactivation and effective strategies to prevent HBV reactivation. Fifteen years of literature were reviewed in order to better understand the reactivation rates of hepatitis B in patients with non-Hodgkin’s lymphoma. Anti-CD20 antibodies continue to be the main medications that can lead to HBV reactivation, and HBV reactivation rates have decreased with increased awareness. HBV reactivation is uncommon when using other novel agents. Entecavir and lamivudine remain the agents of choice to prevent HBV reactivation in high risk patients. In conclusion, the immunosuppressive effect of NHL and its therapy provide a pathway for HBV reactivation, especially in patients treated with anti-CD20 antibody. Since many HBV positive patients are often excluded from clinical trials of novel agents in NHL, more aggressive post-market surveillance of new agents, well-designed best practice advisories, and timely case reports are needed to reduce the incidence of HBV reactivation. Lastly, large prospective investigations coupled with well-utilized best practice advisories need to be conducted to understand the impact of more potent novel NHL therapy on HBV reactivation.

show abstract

Gambaran Hasil Pemeriksaan IMLTD Reaktif Metode CHLIA pada Kasus Reaktif HBsAg dan HCV di UDD PMI Kota Surakarta Tahun 2021

Safitri¹,

Laili²

2023

Indonesian j. on Med. Sci.

View full text Add to dashboard Cite

Hepatitis B merupakan suatu penyakit hati disebabkan oleh virus Hepatitis B yang dapat menyebabkan peradangan hati akut. Hepatitis C termasuk salah satu virus yang dapat menyebabkan infeksi pada sel-sel hati yang dapat menular melalui darah, Mengetahui gambaran hasil pemeriksaan IMLTD reaktif metode CHLIA pada kasus reaktif HBsAg dan HCV di UDD PMI Kota Surakarta tahun 2021 HBsAg reaktif tahun 2021 metode CHLIA 167, berdasarkan periode waktu bulan Maret, April, Agustus 20 (12,0%), berdasarkan rentang usia 25 – 44 tahun 78 (46,7%), berdasarkan jenis kelamin laki-laki 131 (78,4%), berdasarkan golongan darah golongan darah O 67 (40,1%). HCV reaktif tahun 2021 metode CHLIA 30 ,berdasarkan periode waktu bulan Maret 6 (20,0%), berdasarkan rentang usia 25 – 44 tahun 15 (50,0%), berdasarkan jenis kelamin laki-laki 27 (90,0%), berdasarkan golongan darah golongan darah B 14 (46,7%).

show abstract

Diagnosis, Management, and Prevention of Hepatitis B Reactivation

Cited by 3 publications

References 84 publications

Optimizing antiviral agents for hepatitis B management in malignant lymphomas

Optimizing antiviral agents for hepatitis B management in malignant lymphomas

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin’s Lymphoma and Prevention Strategies

Gambaran Hasil Pemeriksaan IMLTD Reaktif Metode CHLIA pada Kasus Reaktif HBsAg dan HCV di UDD PMI Kota Surakarta Tahun 2021

Contact Info

Product

Resources

About